Recommended drug treatment strategies for the alcoholic patient

Drugs

Volumn 56, Issue 4, 1998, Pages 571-585

  Schaffer, A ^a   Naranjo, C A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; NALTREXONE; SEROTONIN UPTAKE INHIBITOR;

ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANXIETY; DEPRESSION; DRUG EFFICACY; HUMAN; MENTAL DISEASE; NEUROBIOLOGY; PATIENT COMPLIANCE; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RECURRENCE RISK; RELAPSE; REVIEW;

ANIMALIA;

EID: 0031767934     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856040-00005     Document Type: Review

References (139)

1. 1. CA Naranjo KE Bremner 1994 Pharmacotherapy of substance use disorders Can J Clin Pharmacol 1 2 55 71 Naranjo CA, Bremner KE. Pharmacotherapy of substance use disorders. Can J Clin Pharmacol 1994; 1(2): 55–71
2. 2. IC Buchan EH Buckley GLS Deacon 1981 Problem drinkers and their problems J R Coll Gen Pract 31 151 3 7277292 1:STN:280:DyaL38%2FhtVektQ%3D%3D Buchan IC, Buckley EH, Deacon GLS, et al. Problem drinkers and their problems. J R Coll Gen Pract 1981; 31: 151–3
3. 3. CA Naranjo V Ozdemir KE Bremner 1994 Diagnosis and pharmacological treatment of alcoholic patients CNS Drugs 1 5 330 40 10.2165/00023210-199401050-00003 Naranjo CA, Ozdemir V, Bremner KE. Diagnosis and pharmacological treatment of alcoholic patients. CNS Drugs 1994; 1(5): 330–40
4. 4. ML Selzer 1971 The Michigan Alcoholism Screening Test: the quest for a new diagnostic instrument Am J Psychiatry 127 89 94 Selzer ML. The Michigan Alcoholism Screening Test: the quest for a new diagnostic instrument. Am J Psychiatry 1971; 127: 89–94
5. 5. D Mayfield G McLeod P Hall 1974 The CAGE questionnaire: validation of a new alcoholism screening instrument Am J Psychiatry 131 117 26 Mayfield D, McLeod G, Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry 1974; 131: 117–26
6. 6. HA Skinner S Holt WJ Sheu 1986 Clinical versus laboratory detection of alcohol abuse: the alcohol clinical index BMJ 292 1703 8 3089362 1:STN:280:DyaL283ntVygsg%3D%3D 10.1136/bmj.292.6537.1703 Skinner HA, Holt S, Sheu WJ, et al. Clinical versus laboratory detection of alcohol abuse: the alcohol clinical index. BMJ 1986; 292: 1703–8
7. 7. JB Saunders OG Aasland 1987 WHO collaborative project on identification and treatment of persons with harmful alcohol consumption: report on phase I. Development of a screening instrument World Health Organization Geneva Saunders JB, Aasland OG. WHO collaborative project on identification and treatment of persons with harmful alcohol consumption: report on phase I. Development of a screening instrument. Geneva: World Health Organization, 1987
8. 8. H Orrego JE Blake Y Israel 1985 Relationship between gamma glutamyltransferase and mean urinary alcohol levels in alcoholics while drinking and after alcohol withdrawal Alcohol Clin Exp Res 9 10 3 2859812 1:CAS:528:DyaL2MXhsVClsLk%3D 10.1111/j.1530-0277.1985.tb05038.x Orrego H, Blake JE, Israel Y. Relationship between gamma glutamyltransferase and mean urinary alcohol levels in alcoholics while drinking and after alcohol withdrawal. Alcohol Clin Exp Res 1985; 9: 10–3
9. 9. TP Whitehead CA Clarke AGW Whitfield 1978 Biochemical and hematological markers of alcohol intake Lancet I 978 81 10.1016/S0140-6736(78)90261-1 Whitehead TP, Clarke CA, Whitfield AGW Biochemical and hematological markers of alcohol intake. Lancet 1978; I: 978–81
10. 10. HA Skinner S Holt R Schuller 1984 Identification of alcohol abuse using laboratory tests and a history of trauma Ann Intern Med 101 847 51 6149716 1:STN:280:DyaL2M%2FksFWnug%3D%3D Skinner HA, Holt S, Schuller R. Identification of alcohol abuse using laboratory tests and a history of trauma. Ann Intern Med 1984; 101: 847–51
11. 11. JB Whitfield WJ Hensley D Bryden 1978 Some laboratory correlates of drinking habits Ann Clin Biochem 15 297 303 32826 1:STN:280:DyaE1M7gt1Wgtw%3D%3D Whitfield JB, Hensley WJ, Bryden D, et al. Some laboratory correlates of drinking habits. Ann Clin Biochem 1978; 15: 297–303
12. 12. J Chick N Kreitman M Plant 1981 Mean cell volume and gamma-glutamyl transpeptidase as markers of drinking in working men Lancet 1I 1249 51 10.1016/S0140-6736(81)92413-2 Chick J, Kreitman N, Plant M. Mean cell volume and gamma-glutamyl transpeptidase as markers of drinking in working men. Lancet 1981; 1I: 1249–51
13. 13. MW Bernadt J Mumford C Taylor 1982 Comparison of questionnaire and laboratory tests in the detection of excessive drinking and alcoholism Lancet I 325 8 10.1016/S0140-6736(82)91579-3 Bernadt MW, Mumford J, Taylor C, et al. Comparison of questionnaire and laboratory tests in the detection of excessive drinking and alcoholism. Lancet 1982; I: 325–8
14. 14. CA Naranjo KE Bremner 1993 Behavioural correlates of alcohol intoxication Addiction 88 47 57 10.1111/j.1360-0443.1993.tb02761.x Naranjo CA, Bremner KE. Behavioural correlates of alcohol intoxication. Addiction 1993; 88: 47–57
15. 15. D Mascord J Smith GA Starmer 1991 The effect of fructose on alcohol metabolism and on the [lactate]/[pyruvate] ratio in man Alcohol Alcohol 26 1 53 9 1854373 1:CAS:528:DyaK3MXksVCjtrg%3D Mascord D, Smith J, Starmer GA, et al. The effect of fructose on alcohol metabolism and on the [lactate]/[pyruvate] ratio in man. Alcohol Alcohol 1991; 26(1): 53–9
16. 16. BP Crownover J Dine La B Bradford 1986 Activation of ethanol metabolism in humans by fructose: importance of experimental design J Pharmacol Exp Ther 2 574 9 Crownover BP, La Dine J, Bradford B, et al. Activation of ethanol metabolism in humans by fructose: importance of experimental design. J Pharmacol Exp Ther 1986; 2: 574–9
17. 17. S Mardel I Phair F O’Dwyer 1994 Intravenous pyridoxine in acute ethanol intoxication Hum Exp Toxicol 13 5 321 3 8043313 1:CAS:528:DyaK2cXlt1OltrY%3D 10.1177/096032719401300507 Mardel S, Phair I, O’Dwyer F, et al. Intravenous pyridoxine in acute ethanol intoxication. Hum Exp Toxicol 1994; 13(5): 321–3
18. 18. V Ozdemir KE Bremner CA Naranjo 1993 Treatment of alcohol withdrawal syndrome Ann Med 26 101 5 10.3109/07853899409147336 Ozdemir V, Bremner KE, Naranjo CA. Treatment of alcohol withdrawal syndrome. Ann Med 1993; 26: 101–5
19. 19. JM Shaw GS Kolesar EM Sellers 1981 Development of optimal treatment tactics for alcohol withdrawal: I Assessment and effectiveness of supportive care. J Clin Psychopharmacol 1 382 9 1:STN:280:DyaL387ktlaitQ%3D%3D Shaw JM, Kolesar GS, Sellers EM, et al. Development of optimal treatment tactics for alcohol withdrawal: I. Assessment and effectiveness of supportive care. J Clin Psychopharmacol 1981; 1: 382–9
20. 20. ME Mayo-Smith 1997 Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guidelines JAMA 278 144 51 9214531 1:CAS:528:DyaK2sXkslajt74%3D 10.1001/jama.1997.03550020076042 Mayo-Smith ME Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guidelines. JAMA 1997; 278: 144–51
21. 21. JT Sullivan K Sykora J Schneiderman 1989 Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar) Br J Addiction 84 1353 7 1:STN:280:DyaK3c%2FovFKnsg%3D%3D 10.1111/j.1360-0443.1989.tb00737.x Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addiction 1989; 84: 1353–7
22. 22. EM Sellers CA Naranjo M Harrison 1983 Diazepam loading: simplified treatment of alcohol withdrawal Clin Pharmacol Ther 34 822 6 6641099 1:STN:280:DyaL2c%2Fls1artw%3D%3D 10.1038/clpt.1983.256 Sellers EM, Naranjo CA, Harrison M, et al. Diazepam loading: simplified treatment of alcohol withdrawal. Clin Pharmacol Ther 1983; 34: 822–6
23. 23. R Saitz MF Mayo-Smith MS Roberts 1994 Individualized treatment for alcohol withdrawal: a randomised double-blind controlled trial JAMA 272 519 23 8046805 1:STN:280:DyaK2czit1CntQ%3D%3D 10.1001/jama.1994.03520070039035 Saitz R, Mayo-Smith MF, Roberts MS, et al. Individualized treatment for alcohol withdrawal: a randomised double-blind controlled trial. JAMA 1994; 272: 519–23
24. 24. MP Peppers 1996 Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease Pharmacotherapy 16 1 49 58 8700792 1:STN:280:DyaK283os1eiug%3D%3D Peppers, MP. Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy 1996; 16(1): 49–58
25. 25. SE Bjorkqvist 1975 Clonidine in alcohol withdrawal Acta Psychiatr Scand 52 256 63 1103576 1:STN:280:DyaE28%2FlvVGqsg%3D%3D 10.1111/j.1600-0447.1975.tb00041.x Bjorkqvist, SE. Clonidine in alcohol withdrawal. Acta Psychiatr Scand 1975; 52: 256–63
26. 26. GR Baumgartner RC Rowen 1987 Clonidine vs chlordiazepoxide in the management of acute alcohol withdrawal syndrome Arch Intern Med 147 1223 6 3300587 1:STN:280:DyaL2s3mvF2gtg%3D%3D 10.1001/archinte.1987.00370070037005 Baumgartner GR, Rowen RC. Clonidine vs chlordiazepoxide in the management of acute alcohol withdrawal syndrome. Arch Intern Med 1987; 147: 1223–6
27. 27. GR Baumgartner RC Rowen 1991 Transdermal clonidine versus chlordiazepoxide in alcohol withdrawal: a randomized, controlled clinical trial South Med J 84 3 312 21 2000517 1:STN:280:DyaK3M7lslSnug%3D%3D 10.1097/00007611-199103000-00006 Baumgartner GR, Rowen RC. Transdermal clonidine versus chlordiazepoxide in alcohol withdrawal: a randomized, controlled clinical trial. South Med J 1991; 84(3): 312–21
28. 28. BJ Robinson GM Robinson TJB Maling 1989 Is clonidine useful in the treatment of alcohol withdrawal? Alcohol Clin Exp Res 13 1 95 8 2646983 1:STN:280:DyaL1M7msVKqug%3D%3D 10.1111/j.1530-0277.1989.tb00290.x Robinson BJ, Robinson GM, Maling TJB, et al. Is clonidine useful in the treatment of alcohol withdrawal? Alcohol Clin Exp Res 1989; 13(1): 95–8
29. 29. B Adinoff 1994 Double-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome: a preliminary finding Alcohol Clin Exp Res 18 4 873 8 7978098 1:STN:280:DyaK2M%2FmvVOmsg%3D%3D 10.1111/j.1530-0277.1994.tb00053.x Adinoff B. Double-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome: a preliminary finding. Alcohol Clin Exp Res 1994; 18(4): 873–8
30. 30. ML Kraus LD Gottlieb RI Horwitz 1985 Randomized clinical trial of atenolol in patients with alcohol withdrawal N Engl J Med 313 905 9 2863754 1:STN:280:DyaL2M3ps1Wksg%3D%3D 10.1056/NEJM198510103131501 Kraus ML, Gottlieb LD, Horwitz RI, et al. Randomized clinical trial of atenolol in patients with alcohol withdrawal. N Engl J Med 1985; 313: 905–9
31. 31. R Malcolm J Ballenger E Sturgis 1989 Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal Am J Psychiatry 146 617 21 2653057 1:STN:280:DyaL1M3is1Smuw%3D%3D Malcolm R, Ballenger J, Sturgis E, et al. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry 1989; 146: 617–21
32. 32. CH Stuppaeck R Pycha C Miller 1992 Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study Alcohol Alcohol 27 2 153 8 1524606 1:STN:280:DyaK38zpvVKqsQ%3D%3D Stuppaeck CH, Pycha R, Miller C, et al. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study. Alcohol Alcohol 1992; 27(2): 153–8
33. 33. D Ames 1990 Oxazepam and carbamazepine for alcohol withdrawal Am J Psychiatry 147 3 375 6 2309968 1:STN:280:DyaK3c7nvVGiuw%3D%3D Ames D. Oxazepam and carbamazepine for alcohol withdrawal. Am J Psychiatry 1990; 147(3): 375–6
34. 34. M Hillbom R Tokola 1989 Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid Alcohol 6 223 6 2500138 1:STN:280:DyaL1M3oslShtA%3D%3D 10.1016/0741-8329(89)90022-0 Hillbom M, Tokola R, et al. Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid. Alcohol 1989; 6: 223–6
35. 35. CA Naranjo EM Sellers 1986 Clinical assessment and pharmacotherapy of the alcohol withdrawal syndrome M Galanter Recent developments in alcoholism. Vol.4 Plenum Press New York 265 81 Naranjo CA, Sellers EM. Clinical assessment and pharmacotherapy of the alcohol withdrawal syndrome. In: Galanter M, editor. Recent developments in alcoholism. Vol.4. New York: Plenum Press, 1986: 265–81
36. 36. R Matz 1995 Barbiturates in alcohol withdrawal Hosp Pract (Off Ed) 30 9 26 1:STN:280:DyaK28%2FgvF2jsQ%3D%3D Matz R. Barbiturates in alcohol withdrawal. Hosp Pract (Off Ed) 1995 Sep 15; 30(9): 26
37. 37. EM Sellers H Kalant 1982 Alcohol withdrawal and delirium tremens EM Pattison E Kaufman Encyclopedic handbook of alcoholism Gardner Press New York 147 66 Sellers EM, Kalant H. Alcohol withdrawal and delirium tremens. In: Pattison EM, Kaufman E, editors. Encyclopedic handbook of alcoholism. New York: Gardner Press, 1982; 147–66
38. 38. R Saitz LS Friedman MF Mayo-Smith 1995 Alcohol withdrawal: a nationwide survey of inpatient treatment practices J Gen Intern Med 10 479 87 8523149 1:STN:280:DyaK287gtVahsQ%3D%3D 10.1007/BF02602395 Saitz R, Friedman LS, Mayo-Smith MF. Alcohol withdrawal: a nationwide survey of inpatient treatment practices. J Gen Intern Med 1995; 10: 479–87
39. 39. MA Gillman FJ Lichtigfeld 1991 Placebo and analgesic nitrous oxide for treatment of the alcohol withdrawal state Br J Psychiatry 159 672 5 1756344 1:STN:280:DyaK38%2Fps1Oqsg%3D%3D 10.1192/bjp.159.5.672 Gillman MA, Lichtigfeld FJ. Placebo and analgesic nitrous oxide for treatment of the alcohol withdrawal state. Br J Psychiatry 1991; 159: 672–5
40. 40. FJ Lichtigfeld MA Gillman 1994 Psychotropic analgesic nitrous oxide and neurotransmitter mechanisms involved in the alcohol withdrawal state Int J Neurosci 76 17 33 7960465 1:STN:280:DyaK2M%2FkvFWgtA%3D%3D 10.3109/00207459408985988 Lichtigfeld FJ, Gillman MA. Psychotropic analgesic nitrous oxide and neurotransmitter mechanisms involved in the alcohol withdrawal state. Int J Neurosci 1994; 76: 17–33
41. 41. R Ojutkangas MA Gillman 1994 Psychotropic analgesic nitrous oxide for treating alcohol withdrawal in an outpatient setting Int J Neurosci 76 35 9 7960466 1:STN:280:DyaK2M%2FkvFWgtQ%3D%3D 10.3109/00207459408985989 Ojutkangas R, Gillman MA. Psychotropic analgesic nitrous oxide for treating alcohol withdrawal in an outpatient setting. Int J Neurosci 1994; 76: 35–9
42. 42. VA Ilyuchina LI Nikitina 1995 Clinical physiological study of the therapeutic effects of phenytoin in acute alcohol withdrawal and the asthenic-autonomic syndrome in patients with chronic alcoholism Alcohol 12 6 511 7 8590611 1:CAS:528:DyaK28Xkt1GltQ%3D%3D 10.1016/0741-8329(95)00036-4 Ilyuchina VA, Nikitina LI. Clinical physiological study of the therapeutic effects of phenytoin in acute alcohol withdrawal and the asthenic-autonomic syndrome in patients with chronic alcoholism. Alcohol 1995; 12(6): 511–7
43. 43. NK Rathlev G D’Onofrio SS Fish 1994 The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures Ann Emerg Med 23 3 513 8 8135426 1:STN:280:DyaK2c7ot1yjug%3D%3D 10.1016/S0196-0644(94)70070-2 Rathlev NK, D’Onofrio G, Fish SS, et al. The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures. Ann Emerg Med 1994; 23(3): 513–8
44. 44. BA Hammer KT Brady 1996 Valproate treatment of alcohol withdrawal and mania [letter] Am J Psychiatry 153 9 1232 8780434 1:STN:280:DyaK28znsVWnsQ%3D%3D Hammer BA, Brady KT. Valproate treatment of alcohol withdrawal and mania [letter]. Am J Psychiatry 1996; 153(9): 1232
45. 45. D Nutt P Glue S Wilson 1993 Flumazenil in alcohol withdrawal Alcohol Alcohol Suppl 2 337 41 7748321 1:STN:280:DyaK2M3mslWktA%3D%3D Nutt D, Glue P, Wilson S, et al. Flumazenil in alcohol withdrawal. Alcohol Alcohol Suppl 1993; 2: 337–41
46. 46. KJ Buck RA Harris 1991 Reversal of alcohol dependence and tolerance by a single administration of flumazenil J Pharmacol Exp Ther 257 984 9 1646333 1:CAS:528:DyaK3MXksVCjt7c%3D Buck KJ, Harris RA. Reversal of alcohol dependence and tolerance by a single administration of flumazenil. J Pharmacol Exp Ther 1991; 257: 984–9
47. 47. MA Whittington JDC Lambert HJ Little 1993 Increases in synaptic activation of calcium current as a mechanism for generation of ethanol withdrawal seizures Alcohol Alcohol Suppl 2 391 4 7748328 1:STN:280:DyaK2M3mslWrtg%3D%3D Whittington MA, Lambert JDC, Little HJ. Increases in synaptic activation of calcium current as a mechanism for generation of ethanol withdrawal seizures. Alcohol Alcohol Suppl 1993; 2: 391–4
48. 48. G Colombo R Agabio C Lobina 1995 Effects of the calcium channel antagonist darodipine on ethanol withdrawal in rats Alcohol Alcohol 30 1 125 31 7748269 1:CAS:528:DyaK2MXltlKjsL8%3D Colombo G, Agabio R, Lobina C, et al. Effects of the calcium channel antagonist darodipine on ethanol withdrawal in rats. Alcohol Alcohol 1995; 30(1): 125–31
49. 49. HS Little SJ Dolin MA Whittington 1993 Calcium channel antagonists prevent adaptive responses to ethanol Alcohol Alcohol Suppl 2 263 7 7748308 1:STN:280:DyaK2M3mslWlsA%3D%3D Little HS, Dolin SJ, Whittington MA. Calcium channel antagonists prevent adaptive responses to ethanol. Alcohol Alcohol Suppl 1993; 2: 263–7
50. 50. B Costall AM Domeney ME Kelly 1993 The effects of 5-HT3 receptor antagonists in models of dependency and withdrawal Alcohol Alcohol Suppl 2 269 73 7748309 1:STN:280:DyaK2M3mslWlsQ%3D%3D Costall B, Domeney AM, Kelly ME, et al. The effects of 5-HT3 receptor antagonists in models of dependency and withdrawal. Alcohol Alcohol Suppl 1993; 2: 269–73
51. 51. PL Hoffman B Tabakoff 1994 The role of the NMDA receptor in ethanol withdrawal EXS 71 61 70 8032173 1:CAS:528:DyaK2cXlsFWis70%3D Hoffman PL, Tabakoff B. The role of the NMDA receptor in ethanol withdrawal. EXS 1994; 71: 61–70
52. 52. A Davido JF Cadranel A Levy 1994 Effects of intravenous administration of dexamethasone in the treatment of alcohol withdrawal syndrome J Clin Gastroenterol 18 2 178 9 8189026 1:STN:280:DyaK2c3ks1WgsA%3D%3D 10.1097/00004836-199403000-00030 Davido A, Cadranel JF, Levy A, et al. Effects of intravenous administration of dexamethasone in the treatment of alcohol withdrawal syndrome. J Clin Gastroenterol 1994; 18(2): 178–9
53. 53. DH Peters D Faulds 1994 Tiapride: a review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome Drugs 47 6 1010 32 7521826 1:STN:280:DyaK2czmsVahuw%3D%3D 10.2165/00003495-199447060-00009 Peters DH, Faulds D. Tiapride: a review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs 1994; 47(6): 1010–32
54. 54. J Ruusa B Bergman 1996 Sex hormones and alcohol withdrawal: does a good supply of testosterone prevent serious symptoms during detoxification? Alcohol 13 2 139 45 8814647 1:CAS:528:DyaK28XislOnsLg%3D 10.1016/0741-8329(95)02025-X Ruusa J, Bergman B. Sex hormones and alcohol withdrawal: does a good supply of testosterone prevent serious symptoms during detoxification? Alcohol 1996; 13(2): 139–45
55. 55. JR Volpicelli LA Volpicelli CR O’Brien 1995 Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment Alcohol Alcohol 30 6 789 98 8679021 1:CAS:528:DyaK28Xht12hsLY%3D Volpicelli JR, Volpicelli LA, O’Brien CR Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment. Alcohol Alcohol 1995; 30(6): 789–98
56. 56. MJ Bohn HR Kranzler D Beazoglou 1994 Naltrexone and brief counseling to reduce heavy drinking Am J Addict 3 91 9 Bohn MJ, Kranzler HR, Beazoglou D, et al. Naltrexone and brief counseling to reduce heavy drinking. Am J Addict 1994; 3: 91–9
57. 57. D Davidson R Swift E Fitz 1996 Naltrexone increases the latency to drink alcohol in social drinkers Alcohol Clin Exp Res 20 4 732 9 8800392 1:CAS:528:DyaK28XksVOktLY%3D 10.1111/j.1530-0277.1996.tb01679.x Davidson D, Swift R, Fitz E. Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res 1996; 20(4): 732–9
58. 58. RM Swift W Whelihan O Kuznetsov 1994 Naltrexone-induced alterations in human ethanol intoxication Am J Psychiatry 151 1463 7 8092339 1:STN:280:DyaK2cznvFamtg%3D%3D Swift RM, Whelihan W, Kuznetsov O, et al. Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 1994; 151: 1463–7
59. 59. SS O’Malley AJ Jaffe G Chang 1992 Naltrexone and coping skills therapy for alcohol dependence Arch Gen Psychiatry 49 881 7 1444726 10.1001/archpsyc.1992.01820110045007 O’Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry 1992; 49: 881–7
60. 60. JR Volpicelli AI Alterman M Hayashida 1992 Naltrexone in the treatment of alcohol dependence Arch Gen Psychiatry 49 876 80 1345133 1:STN:280:DyaK3s%2FnsVarsQ%3D%3D 10.1001/archpsyc.1992.01820110040006 Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876–80
61. 61. SS O’Malley RS Croop JM Wroblewski 1995 Naltrexone in the treatment of alcohol dependence: a combined analysis of two trials Psychiatr Ann 25 11 681 8 O’Malley SS, Croop RS, Wroblewski JM, et al. Naltrexone in the treatment of alcohol dependence: a combined analysis of two trials. Psychiatr Ann 1995; 25(11): 681–8
62. 62. SS O’Malley AJ Jaffe G Chang 1996 Six-month follow-up of naltrexone and psychotherapy for alcohol dependence Arch Gen Psychiatry 53 217 24 8611058 10.1001/archpsyc.1996.01830030039007 O’Malley SS, Jaffe AJ, Chang G, et al. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 1996; 53: 217–24
63. 63. JR Volpicelli KL Clay NT Watson 1995 Naltrexone in the treatment of alcoholism: predicting response to naltrexone J Clin Psychiatry 56 7 39 44 7673104 Volpicelli JR, Clay KL, Watson NT, et al. Naltrexone in the treatment of alcoholism: predicting response to naltrexone. J Clin Psychiatry 1995; 56 Suppl. 7: 39–44
64. 64. SS O’Malley AJ Jaffe S Rode 1996 Experience of a ‘slip’ among alcoholics treated with naltrexone or placebo Am J Psychiatry 153 281 3 8561215 O’Malley SS, Jaffe AJ, Rode S, et al. Experience of a ‘slip’ among alcoholics treated with naltrexone or placebo. Am J Psychiatry 1996; 153: 281–3
65. 65. JR Volpicelli NT Watson AC King 1995 Effect of naltrexone on alcohol ‘high’ in alcoholics Am J Psychiatry 152 613 5 7694913 1:STN:280:DyaK2M3gvV2htw%3D%3D Volpicelli JR, Watson NT, King AC, et al. Effect of naltrexone on alcohol ‘high’ in alcoholics. Am J Psychiatry 1995; 152: 613–5
66. 66. JR Volpicelli KC Rhines JS Rhines 1997 Naltrexone and alcohol dependence: role of subject compliance Arch Gen Psychiatry 54 737 42 9283509 1:CAS:528:DyaK2sXls1ygtrc%3D 10.1001/archpsyc.1997.01830200071010 Volpicelli JR, Rhines KC, Rhines JS, et al. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997; 54: 737–42
67. 67. BJ Berg HM Pettinati JR Volpicelli 1996 A risk-benefit assessment of naltrexone in the treatment of alcohol dependence Drug Saf 15 4 274 82 8905252 1:CAS:528:DyaK28XmvFKmtr4%3D 10.2165/00002018-199615040-00005 Berg BJ, Pettinati HM, Volpicelli JR. A risk-benefit assessment of naltrexone in the treatment of alcohol dependence. Drug Saf 1996; 15(4): 274–82
68. 68. RZ Litten 1996 International update: new findings on promising medications Alcohol Clin Exp Res 20 8 216 10.1111/j.1530-0277.1996.tb01779.x Litten RZ. International update: new findings on promising medications. Alcohol Clin Exp Res 1996; 20(8): 216A-8A
69. 69. H Sass M Soyka K Mann 1996 Relapse prevention by acamprosate Arch Gen Psychiatry 53 673 80 8694680 1:CAS:528:DyaK28Xltlantrg%3D 10.1001/archpsyc.1996.01830080023006 Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate. Arch Gen Psychiatry 1996; 53: 673–80
70. 70. AB Whitworth F Fischer OM Lesch 1996 Comparison of acamprosate and placebo in long-term treatment of alcohol dependence Lancet 347 1438 42 8676626 1:CAS:528:DyaK28XjvVSntbo%3D 10.1016/S0140-6736(96)91682-7 Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996; 347: 1438–42
71. 71. FM Paille JD Guelpi AC Perkins 1995 Double-blind randomised multicentre trial of acamprosate in maintaining abstinence from alcohol Alcohol Alcohol 30 2 239 47 7662044 1:STN:280:DyaK2MzptFSjtA%3D%3D Paille FM, Guelpi JD, Perkins AC, et al. Double-blind randomised multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995; 30(2): 239–47
72. 72. I Pelc P Verbanck O Bon Le 1997 Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients Br J Psychiatry 171 73 7 9328500 1:STN:280:DyaK2svmvFShug%3D%3D 10.1192/bjp.171.1.73 Pelc I, Verbanck P, Le Bon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. Br J Psychiatry 1997; 171: 73–7
73. 73. H Sass AS Potgieter 1995 Results from a pooled analysis of 11 European trials comparing acamprosate and placebo in the treatment of alcohol dependence [abstract] Alcohol Alcohol 30 4 551 Sass H, Potgieter AS. Results from a pooled analysis of 11 European trials comparing acamprosate and placebo in the treatment of alcohol dependence [abstract]. Alcohol Alcohol 1995; 30(4): 551
74. 74. MI Wilde AJ Wagstaff 1997 Acamprosate: a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification Drugs 53 6 1038 53 9179530 1:CAS:528:DyaK2sXjvFagtLw%3D 10.2165/00003495-199753060-00008 Wilde MI, Wagstaff AJ. Acamprosate: a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 1997 Jun; 53(6): 1038–53
75. 75. DI Kabel F Petty 1996 A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment Alcohol Clin Exp Res 20 4 780 4 8800399 1:CAS:528:DyaK28XksVOktLc%3D 10.1111/j.1530-0277.1996.tb01686.x Kabel DI, Petty F. A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res 1996; 20(4): 780–4
76. 76. HR Kranzler JA Burleson P Korner 1995 Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics Am J Psychiatry 152 391 7 7864265 1:STN:280:DyaK2M7mvVCrtw%3D%3D Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995; 152: 391–7
77. 77. HR Kranzler JA Burleson J Brown 1996 Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics Alcohol Clin Exp Res 20 9 1534 41 8986200 1:CAS:528:DyaK2sXms1SrsQ%3D%3D 10.1111/j.1530-0277.1996.tb01696.x Kranzler HR, Burleson JA, Brown J, et al. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res 1996; 20(9): 1534–41
78. 78. CA Naranjo CX Poulos KE Bremner 1994 Fluoxetine attenuates alcohol intake and desire to drink Int Clin Psychopharmacol 9 3 163 72 7814825 1:STN:280:DyaK2M7hsVegtw%3D%3D 10.1097/00004850-199409000-00004 Naranjo CA, Poulos CX, Bremner KE, et al. Fluoxetine attenuates alcohol intake and desire to drink. Int Clin Psychopharmacol 1994; 9(3): 163–72
79. 79. CA Naranjo KE Bremner KL Lanctot 1995 Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems Addiction 90 87 99 7888983 1:STN:280:DyaK2M7psFKjsQ%3D%3D 10.1111/j.1360-0443.1995.tb01013.x Naranjo CA, Bremner KE, Lanctot KL. Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction 1995; 90: 87–99
80. 80. CA Naranjo KE Bremenr 1998 Gender variations in response to citalopram and a brief psychosocial intervention for alcohol dependence [abstract] Clin Pharmacol Ther 63 2 205 Naranjo CA, Bremenr KE. Gender variations in response to citalopram and a brief psychosocial intervention for alcohol dependence [abstract]. Clin Pharmacol Ther 1998; 63(2): 205
81. 81. J Balldin U Berggren J Engel 1994 Effect of citalopram on alcohol intake in heavy drinkers Alcohol Clin Exp Res 18 5 1133 6 7847595 1:STN:280:DyaK2M7ltVamuw%3D%3D 10.1111/j.1530-0277.1994.tb00093.x Balldin J, Berggren U, Engel J, et al. Effect of citalopram on alcohol intake in heavy drinkers. Alcohol Clin Exp Res 1994; 18(5): 1133–6
82. 82. J Tiihonen OP Ryynanen J Kauhanen 1996 Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study Pharmacopsychiatry 29 27 9 8852531 1:CAS:528:DyaK2sXjs1Cgu7c%3D 10.1055/s-2007-979538 Tiihonen J, Ryynanen OP, Kauhanen J, et al. Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study. Pharmacopsychiatry 1996; 29: 27–9
83. 83. HR Kranzler F Boca Del P Korner 1993 Adverse effects limit the usefulness of fluvoxamine for the treatment of alcoholism J Subst Abuse Treat 10 283 7 8315702 1:STN:280:DyaK3szgtF2rtA%3D%3D 10.1016/0740-5472(93)90076-E Kranzler HR, Del Boca F, Korner P, et al. Adverse effects limit the usefulness of fluvoxamine for the treatment of alcoholism. J Subst Abuse Treat 1993; 10: 283–7
84. 84. BA Johnson GM Campling P Griffiths 1993 Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers Psychopharmacology 112 142 4 7871004 1:CAS:528:DyaK3sXms1CmsLo%3D 10.1007/BF02247375 Johnson BA, Campling GM, Griffiths P, et al. Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers. Psychopharmacology 1993; 112: 142–4
85. 85. RM Swift D Davidson W Whelihan 1996 Ondansetron alters human alcohol intoxication Biol Psychiatry 40 514 21 8879472 1:CAS:528:DyaK28XmtFeqsr8%3D 10.1016/0006-3223(95)00432-7 Swift RM, Davidson D, Whelihan W, et al. Ondansetron alters human alcohol intoxication. Biol Psychiatry 1996; 40: 514–21
86. 86. EM Sellers T Toneatto MK Romach 1994 Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence Alcohol Clin Exp Res 18 4 879 85 7978099 1:STN:280:DyaK2M%2FmvVOmsw%3D%3D 10.1111/j.1530-0277.1994.tb00054.x Sellers EM, Toneatto T, Romach MK, et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1994; 18(4): 879–85
87. 87. CA Naranjo CX Poulos KL Lanctot 1995 Ritanserin, a central 5-HT2 antagonist, in heavy social drinkers: desire to drink, alcohol intake and related effects Addiction 90 893 905 7663312 1:STN:280:DyaK2Mzpt1emtQ%3D%3D 10.1111/j.1360-0443.1995.tb03499.x Naranjo CA, Poulos CX, Lanctot KL, et al. Ritanserin, a central 5-HT2 antagonist, in heavy social drinkers: desire to drink, alcohol intake and related effects. Addiction 1995; 90: 893–905
88. 88. JE Peachey HM Annis ER Bornstein 1989 Calcium carbimide in alcoholism treatment: part 1 A placebo-controlled, double-blind clinical trial of short-term efficacy. Br J Addict 84 877 87 1:STN:280:DyaL1MznsFOgtA%3D%3D Peachey JE, Annis HM, Bornstein ER, et al. Calcium carbimide in alcoholism treatment: part 1. A placebo-controlled, double-blind clinical trial of short-term efficacy. Br J Addict 1989; 84: 877–87
89. 89. RK Fuller L Branchey DR Brightwell 1986 Disulfiram treatment of alcoholism: a Veterans’ Administration Cooperative Study JAMA 256 1449 55 3528541 1:STN:280:DyaL28zgvVehtA%3D%3D 10.1001/jama.1986.03380110055026 Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism: a Veterans’ Administration Cooperative Study. JAMA 1986; 256: 1449–55
90. 90. V Ozdemir U Busto T Einarson 1994 Meta-analysis of the efficacy of alcohol-sensitizing agents in alcohol dependence [abstract] Clin Pharmacol Ther 55 134 Ozdemir V, Busto U, Einarson T, et al. Meta-analysis of the efficacy of alcohol-sensitizing agents in alcohol dependence [abstract]. Clin Pharmacol Ther 1994; 55: 134
91. 91. JC Hughes CCH Cook 1997 The efficacy of disuffiram: a review of outcome studies Addiction 92 4 381 95 9177060 1:STN:280:DyaK2szitVWktA%3D%3D 10.1111/j.1360-0443.1997.tb03370.x Hughes JC, Cook CCH. The efficacy of disuffiram: a review of outcome studies. Addiction 1997; 92(4): 381–95
92. 92. J Chick K Gough W Falkowski 1992 Disuffiram treatment of alcoholism Br J Psychiatry 161 84 9 1638335 1:STN:280:DyaK38zks1akug%3D%3D 10.1192/bjp.161.1.84 Chick J, Gough K, Falkowski W, et al. Disuffiram treatment of alcoholism. Br J Psychiatry 1992; 161: 84–9
93. 93. TJ O’Farrell JP Allen RZ Litten 1995 Disuffiram (Antabuse) contracts in treatment of alcoholism NIDA Res Monogr 150 65 91 8742773 O’Farrell TJ, Allen JP, Litten RZ. Disuffiram (Antabuse) contracts in treatment of alcoholism. NIDA Res Monogr 1995; 150: 65–91
94. 94. CA Naranjo M Dongier KE Bremner 1997 Long-acting injectable bromocriptine does not reduce relapse in alcoholics Addiction 92 969 78 9376779 1:STN:280:DyaK1c%2FisF2msA%3D%3D 10.1111/j.1360-0443.1997.tb02976.x Naranjo CA, Dongier M, Bremner KE. Long-acting injectable bromocriptine does not reduce relapse in alcoholics. Addiction 1997; 92: 969–78
95. 95. BR Lawford RM Young JA Rowell 1995 Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele Nat Med 1 4 337 41 7585063 1:CAS:528:DyaK2MXkvFCitrc%3D 10.1038/nm0495-337 Lawford BR, Young RM, Rowell JA, et al. Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nat Med 1995; 1(4): 337–41
96. 96. JC Froehlich TK Li 1993 Opioid peptides M Galanter Recent developments in alcoholism. Vol. 11: Ten years of progress Plenum Press New York Froehlich JC, Li TK. Opioid peptides. In: Galanter M, editor. Recent developments in alcoholism. Vol. 11: Ten years of progress. New York: Plenum Press, 1993
97. 97. RM Swift 1995 Effect of naltrexone on human alcohol consumption J Clin Psychiatry 56 7 24 9 7673102 Swift, RM. Effect of naltrexone on human alcohol consumption. J Clin Psychiatry 1995; 56 Suppl. 7: 24–9
98. 98. C Gianoulakis JP Waele de 1994 Genetics of alcoholism: role of the endogenous opioid system Metab Brain Dis 9 2 105 26 8072460 1:CAS:528:DyaK2cXltlWisr4%3D 10.1007/BF01999765 Gianoulakis C, de Waele JP. Genetics of alcoholism: role of the endogenous opioid system. Metab Brain Dis 1994; 9(2): 105–26
99. 99. AJ Jaffe B Rounsaville RS Schottenfeld 1996 Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching J Consult Clin Psychol 64 5 1044 53 8916634 1:STN:280:DyaK2s%2FnsVSrtA%3D%3D 10.1037/0022-006X.64.5.1044 Jaffe AJ, Rounsaville B, Schottenfeld RS, et al. Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol 1996; 64(5): 1044–53
100. 100. RF Anton 1996 Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions Alcohol Alcohol 31 1 43 53 8737000 1:CAS:528:DyaK28XjvVyqs7o%3D Anton RF. Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. Alcohol Alcohol 1996; 31 Suppl. 1: 43–53
101. 101. JE Mitchell JE Morley AS Levine 1987 High dose naltrexone and dietary counselling for obesity Biol Psychiatry 22 35 42 3790639 1:STN:280:DyaL2s%2Fns1yjtg%3D%3D 10.1016/0006-3223(87)90127-2 Mitchell JE, Morley JE, Levine AS, et al. High dose naltrexone and dietary counselling for obesity. Biol Psychiatry 1987; 22: 35–42
102. 102. RL Atkinson LK Berke CR Drake 1985 Effects of long-term therapy with naltrexone on body weight in obesity Clin Pharmacol Ther 38 4 419 22 4042525 1:STN:280:DyaL28%2FgtlWktA%3D%3D 10.1038/clpt.1985.197 Atkinson RL, Berke LK, Drake CR, et al. Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther 1985; 38(4): 419–22
103. 103. LD Reid LR Gardell S Chattopadhyay 1996 Periodic naltrexone and propensity to take alcoholic beverage Alcohol Clin Exp Res 20 8 1329 34 8947306 1:CAS:528:DyaK2sXivVeqtA%3D%3D 10.1111/j.1530-0277.1996.tb01130.x Reid LD, Gardell LR, Chattopadhyay S, et al. Periodic naltrexone and propensity to take alcoholic beverage. Alcohol Clin Exp Res 1996; 20(8): 1329–34
104. 104. SS O’Malley 1995 Integration of opioid antagonists and psychosocial therapy in the treatment of narcotic and alcohol dependence J Clin Psychiatry 56 7 30 8 7673103 O’Malley SS. Integration of opioid antagonists and psychosocial therapy in the treatment of narcotic and alcohol dependence. J Clin Psychiatry 1995; 56 Suppl. 7: 30–8
105. 105. Farren CK, Catapano D, OMalley SS. Sertraline with naltrexone versus naltrexone alone in the treatment of alcohol dependence [abstract no. NR316]. Annual Meeting of the American Psychiatric Association; 1997 May 17–22: San Diego
106. 106. BJ Mason EC Ritvo RO Morgan 1994 A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence Alcohol Clin Exp Res 18 5 1162 7 7847600 1:STN:280:DyaK2M7ltValtg%3D%3D 10.1111/j.1530-0277.1994.tb00098.x Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 1994; 18(5): 1162–7
107. 107. KE Bremner CA Naranjo 1994 Serotonin-altering medications in the treatment of alcohol dependence: a review Can J Clin Pharmacol 1 3/4 126 32 Bremner KE, Naranjo CA. Serotonin-altering medications in the treatment of alcohol dependence: a review. Can J Clin Pharmacol 1994; 1(3/4): 126–32
108. 108. CA Naranjo EM Sellers JT Sullivan 1987 The serotonin uptake inhibitor citalopram attenuates ethanol intake Clin Pharmacol Ther 41 266 74 3469057 1:STN:280:DyaL2s7jt1Sitw%3D%3D 10.1038/clpt.1987.27 Naranjo CA, Sellers EM, Sullivan JT, et al. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther 1987; 41: 266–74
109. 109. CA Naranjo CX Poulos KE Bremner 1992 Citalopram decreases desirability, liking and consumption of alcohol in alcohol-dependent drinkers Clin Pharmacol Ther 51 729 39 1535302 1:CAS:528:DyaK38XltVKitr4%3D 10.1038/clpt.1992.85 Naranjo CA, Poulos CX, Bremner KE, et al. Citalopram decreases desirability, liking and consumption of alcohol in alcohol-dependent drinkers. Clin Pharmacol Ther 1992; 51: 729–39
110. 110. F Estevez S Parrillo M Giusti 1995 Single-dose ritanserin and alcohol in healthy volunteers: a placebo-controlled trial Alcohol 12 6 541 5 8590616 1:CAS:528:DyaK28Xkt1Gksg%3D%3D 10.1016/0741-8329(95)00041-0 Estevez F, Parrillo S, Giusti M, et al. Single-dose ritanserin and alcohol in healthy volunteers: a placebo-controlled trial. Alcohol 1995; 12(6): 541–5
111. 111. C Wright RD Moore 1990 Disulfiram treatment of alcoholism Am J Med 88 647 55 2189310 1:STN:280:DyaK3c3ms1ynug%3D%3D 10.1016/0002-9343(90)90534-K Wright C, Moore RD. Disulfiram treatment of alcoholism. Am J Med 1990; 88: 647–55
112. 112. P Banys 1988 The clinical use of disulfiram (Antabuse): a review J Psychoactive Drugs 20 243 60 3069984 1:STN:280:DyaL1M7nslOruw%3D%3D 10.1080/02791072.1988.10472495 Banys P. The clinical use of disulfiram (Antabuse): a review. J Psychoactive Drugs 1988; 20: 243–60
113. 113. SL Dilts SL Dilts Jr 1996 Assessing liver function before initiating disulfiram therapy Am J Psychiatry 153 11 1504 8890693 1:STN:280:DyaK2s%2FksFOmuw%3D%3D Dilts SL, Dilts Jr SL. Assessing liver function before initiating disulfiram therapy. Am J Psychiatry 1996; 153(11): 1504
114. 114. LG Schmidt M Dettling K-J Graef 1996 Reduced dopaminergic function in alcoholics is related to severe dependence Biol Psychiatry 39 193 8 8837980 1:STN:280:DyaK28vjsFSqtg%3D%3D 10.1016/0006-3223(95)00078-X Schmidt LG, Dettling M, Graef K-J, et al. Reduced dopaminergic function in alcoholics is related to severe dependence. Biol Psychiatry 1996; 39: 193–8
115. 115. G Addolorato E Castelli GF Stefanini 1996 An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol-dependent subjects Alcohol Alcohol 31 4 341 5 8879280 1:CAS:528:DyaK28XlvF2ku7o%3D Addolorato G, Castelli E, Stefanini GF, et al. An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol-dependent subjects. Alcohol Alcohol 1996; 31(4): 341–5
116. 116. NN Aliyev 1993 Trial of interferon in chronic alcoholism [letter] Psychiatry Res 54 307 8 10.1016/0165-1781(94)90025-6 Aliyev NN. Trial of interferon in chronic alcoholism [letter]. Psychiatry Res 1993; 54: 307–8
117. 117. G Daynes MA Gillman 1994 Psychotropic analgesic nitrous oxide prevents craving after withdrawal for alcohol, cannabis and tobacco Int J Neurosci 76 13 6 7960461 1:STN:280:DyaK2M%2FkvFWgsA%3D%3D 10.3109/00207459408985987 Daynes G, Gillman MA. Psychotropic analgesic nitrous oxide prevents craving after withdrawal for alcohol, cannabis and tobacco. Int J Neurosci 1994; 76: 13–6
118. 118. EC Penick BJ Powell EJ Nickel 1994 Co-morbidity of lifetime psychiatric disorder among male alcoholic patients Alcohol Clin Exp Res 18 6 1289 93 7695019 1:STN:280:DyaK2M3gvFSnsg%3D%3D 10.1111/j.1530-0277.1994.tb01425.x Penick EC, Powell BJ, Nickel EJ, et al. Co-morbidity of lifetime psychiatric disorder among male alcoholic patients. Alcohol Clin Exp Res 1994; 18(6): 1289–93
119. 119. EV Nunes PJ McGrath FM Quitkin 1993 Imipramine treatment of alcoholism with comorbid depression Am J Psychiatry 150 963 5 8494079 1:STN:280:DyaK3s3mtlamtg%3D%3D Nunes EV, McGrath PJ, Quitkin FM, et al. Imipramine treatment of alcoholism with comorbid depression. Am J Psychiatry 1993; 150: 963–5
120. 120. PJ McGrath EV Nunes JW Stewart 1996 Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial Arch Gen Psychiatry 53 232 40 8611060 1:CAS:528:DyaK28XitV2mtb8%3D 10.1001/archpsyc.1996.01830030054009 McGrath PJ, Nunes EV, Stewart JW, et al. Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry 1996; 53: 232–40
121. 121. BJ Mason JH Kocsis EC Ritvo 1996 A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression JAMA 275 10 761 7 8598592 1:CAS:528:DyaK28XitlKlt78%3D 10.1001/jama.1996.03530340025025 Mason BJ, Kocsis JH, Ritvo EC, et al. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996; 275(10): 761–7
122. 122. JR Cornelius IM Salloum MD Cornelius 1993 Fluoxetine trial in suicidal depressed alcoholics Psychopharmacol Bull 29 195 9 8290665 1:STN:280:DyaK2c7itVSnsQ%3D%3D Cornelius JR, Salloum IM, Cornelius MD, et al. Fluoxetine trial in suicidal depressed alcoholics. Psychopharmacol Bull 1993; 29: 195–9
123. 123. JR Cornelius IM Salloum JG Ehler 1997 Fluoxetine in depressed patients: a double-blind, placebo-controlled trial Arch Gen Psychiatry 54 700 5 9283504 1:CAS:528:DyaK2sXls1ygtrk%3D 10.1001/archpsyc.1997.01830200024004 Cornelius JR, Salloum IM, Ehler JG, et al. Fluoxetine in depressed patients: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54: 700–5
124. 124. HR Kranzler JA Burleson FK Boca Del 1994 Buspirone treatment of anxious alcoholics: a placebo-controlled trial Arch Gen Psychiatry 51 720 31 8080349 1:STN:280:DyaK2czmtFGrug%3D%3D 10.1001/archpsyc.1994.03950090052008 Kranzler HR, Burleson JA, Del Boca FK, et al. Buspirone treatment of anxious alcoholics: a placebo-controlled trial. Arch Gen Psychiatry 1994; 51: 720–31
125. 125. TS Malec EA Malec M Dongier 1996 Efficacy of buspirone in alcohol dependence: a review Alcohol Clin Exp Res 20 5 853 8 8865960 1:CAS:528:DyaK2sXhtFCrsLc%3D 10.1111/j.1530-0277.1996.tb05263.x Malec TS, Malec EA, Dongier M. Efficacy of buspirone in alcohol dependence: a review. Alcohol Clin Exp Res 1996; 20(5): 853–8
126. 126. KT Brady SC Sonne JM Roberts 1995 Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence J Clin Psychiatry 56 502 5 7592501 1:STN:280:DyaK28%2FntFyiuw%3D%3D Brady KT, Sonne SC, Roberts JM. Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. J Clin Psychiatry 1995; 56: 502–5
127. 127. BJ Powell J Campbell JF Landon 1995 A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders Alcohol Clin Exp Res 19 2 462 8 7625583 1:STN:280:DyaK2MzltFGhtA%3D%3D 10.1111/j.1530-0277.1995.tb01532.x Powell BJ, Campbell J, Landon JF, et al. A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders. Alcohol Clin Exp Res 1995; 19(2): 462–8
128. 128. EC Penick BJ Powell J Campbell 1996 Pharmacological treatment for antisocial personality disorder alcoholics: a preliminary study Alcohol Clin Exp Res 20 3 477 84 8727240 1:CAS:528:DyaK28XjslertbY%3D 10.1111/j.1530-0277.1996.tb01078.x Penick EC, Powell BJ, Campbell J, et al. Pharmacological treatment for antisocial personality disorder alcoholics: a preliminary study. Alcohol Clin Exp Res 1996; 20(3): 477–84
129. 129. KT Brady SC Sonne R Anton 1995 Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study J Clin Psychiatry 56 3 118 21 7883730 1:STN:280:DyaK2M7ovFOmsQ%3D%3D Brady KT, Sonne SC, Anton R, et al. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry 1995; 56(3): 118–21
130. 130. KT Brady S Sonne RB Lydiard 1994 Valproate treatment of comorbid panic disorder and affective disorders in two alcoholic patients [letter] J Clin Psychopharmacol 14 1 81 2 8151011 1:STN:280:DyaK2c3gtFCgug%3D%3D 10.1097/00004714-199402000-00015 Brady KT, Sonne S, Lydiard RB. Valproate treatment of comorbid panic disorder and affective disorders in two alcoholic patients [letter]. J Clin Psychopharmacol 1994; 14(1): 81–2
131. 131. MA Schuckit JE Tipp M Bergman 1997 Comparison of induced and independent major depressive disorders in 2945 alcoholics Am J Psychiatry 154 948 57 9210745 1:STN:280:DyaK2szlsVCksQ%3D%3D Schuckit MA, Tipp JE, Bergman M, et al. Comparison of induced and independent major depressive disorders in 2945 alcoholics. Am J Psychiatry 1997; 154: 948–57
132. 132. KM Davidson 1995 Diagnosis of depression in alcohol dependence: changes in prevalence with drinking status Br J Psychiatry 166 199 204 7728364 1:STN:280:DyaK2M3ksFGkuw%3D%3D 10.1192/bjp.166.2.199 Davidson KM. Diagnosis of depression in alcohol dependence: changes in prevalence with drinking status. Br J Psychiatry 1995; 166: 199–204
133. 133. CA Dackis MS Gold ALC Pottash 1986 Evaluating depression in alcoholics Psychiatry Res 17 105 9 3961028 1:STN:280:DyaL287nvVWisw%3D%3D 10.1016/0165-1781(86)90065-X Dackis CA, Gold MS, Pottash ALC, et al. Evaluating depression in alcoholics. Psychiatry Res 1986; 17: 105–9
134. 134. EC Penick BJ Powell BI Liskow 1988 The stability of coexisting psychiatric syndromes in alcoholic men after one year J Stud Alcohol 49 395 405 3270510 1:STN:280:DyaL1M7htFGltg%3D%3D Penick EC, Powell BJ, Liskow BI, et al. The stability of coexisting psychiatric syndromes in alcoholic men after one year. J Stud Alcohol 1988; 49: 395–405
135. 135. SF Greenfield RD Weiss LR Muenz 1998 The effect of depression on return to drinking: a prospective study Arch Gen Psychiatry 55 259 65 9510220 1:STN:280:DyaK1c7mvFSguw%3D%3D 10.1001/archpsyc.55.3.259 Greenfield SF, Weiss RD, Muenz LR. The effect of depression on return to drinking: a prospective study. Arch Gen Psychiatry 1998; 55: 259–65
136. 136. DA Regier ME Farmer DS Rae 1990 Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study JAMA 264 2511 8 2232018 1:STN:280:DyaK3M%2FjvFOiug%3D%3D 10.1001/jama.1990.03450190043026 Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990; 264: 2511–8
137. 137. HR Kranzler 1996 Evaluation and treatment of anxiety symptoms and disorders in alcoholics J Clin Psychiatry 57 7 15 21 8690692 Kranzler HR. Evaluation and treatment of anxiety symptoms and disorders in alcoholics. J Clin Psychiatry 1996; 57 Suppl. 7: 15–21
138. 138. E Malec T Malec MA Gagne 1996 Buspirone in the treatment of alcohol dependence: a placebo-controlled trial Alcohol Clin Exp Res 20 2 307 12 8730222 1:CAS:528:DyaK28XislKjurY%3D 10.1111/j.1530-0277.1996.tb01644.x Malec E, Malec T, Gagne MA, et al. Buspirone in the treatment of alcohol dependence: a placebo-controlled trial. Alcohol Clin Exp Res 1996; 20(2): 307–12
139. 139. RC Kessler RM Crum LA Warner 1997 Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the national comorbidity survey Arch Gen Psychiatry 54 313 21 9107147 1:STN:280:DyaK2s3mtFWqsQ%3D%3D 10.1001/archpsyc.1997.01830160031005 Kessler RC, Crum RM, Warner LA, et al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the national comorbidity survey. Arch Gen Psychiatry 1997; 54: 313–21